• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Camurus

537.00 SEK

+4.78 %

Less than 1K followers

CAMX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+4.78 %
+1.13 %
+13.29 %
-12.82 %
-9.75 %
+3.57 %
+97.43 %
+165.19 %
+788.69 %

Camurus operates in biotechnology. The company is operated as a research-based pharmaceutical company that develops and distributes products for the treatment of severe and chronic diseases. Diseases treated with the company's products include, for example, cancer, endocrine disorders and patients with opioid addiction. Camurus runs development projects under its own management and in partnership with international pharmaceutical companies. The company is headquartered in Lund.

Read more
Market cap
32.21B SEK
Turnover
57.43M SEK
Revenue
2.27B
EBIT %
38.58 %
P/E
43.24
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
15.7
2026

Interim report Q2'26

5.11
2026

Interim report Q3'26

All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release6/1/2026, 3:00 PM

Camurus AB: Camurus announces expansion of Lilly collaboration

Camurus
Regulatory press release5/28/2026, 6:30 PM

Camurus AB: Camurus' Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company's commitments under the Performance Share Plan 2026/2029

Camurus
Regulatory press release5/28/2026, 5:00 PM

Camurus AB: Resolutions at the annual general meeting 2026 in Camurus

Camurus

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release5/21/2026, 8:00 AM

Camurus AB: Camurus to present at Jefferies Global Healthcare Conference

Camurus
Press release5/13/2026, 12:47 PM

Redeye: Camurus (Q1 review): Revenues Below Expectations, but Robust Patient Growth

Camurus
Camurus, Audiocast, Q1'26
Webcast5/12/2026, 12:00 PM

Camurus, Audiocast, Q1'26

Camurus
Regulatory press release5/12/2026, 5:00 AM

Camurus AB: Camurus' Interim Report January-March 2026

Camurus
Regulatory press release4/29/2026, 8:00 AM

Camurus AB: Camurus Annual Report for 2025

Camurus
Regulatory press release4/24/2026, 6:00 AM

Notice of annual general meeting 2026 in Camurus AB (publ)

Camurus
Regulatory press release3/31/2026, 5:00 AM

Camurus AB: Change in number of shares and votes in Camurus

Camurus
Regulatory press release2/27/2026, 2:30 PM

Camurus AB: Change in number of shares and votes in Camurus

Camurus
Press release2/18/2026, 10:25 AM

Redeye: Camurus (Q4 review): Temporary UK Setback

Camurus
Press release2/17/2026, 7:00 AM

Camurus AB: Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer

Camurus
Camurus, Audiocast, Q4'25
Webcast2/12/2026, 1:00 PM

Camurus, Audiocast, Q4'25

Camurus
Regulatory press release2/12/2026, 6:00 AM

Camurus AB: Camurus' Full Year Report 2025

Camurus
Regulatory press release1/9/2026, 2:10 PM

Camurus AB: Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly

Camurus
Regulatory press release12/30/2025, 6:00 AM

Camurus AB: Change in number of shares and votes in Camurus

Camurus
Press release12/16/2025, 10:30 AM

Camurus AB: Camurus and Gubra enter into a collaboration and license agreement to develop a long-acting treatment for hypoparathyroidism

Camurus
Regulatory press release11/28/2025, 6:00 AM

Camurus AB: Change in number of shares and votes in Camurus

Camurus
Regulatory press release11/13/2025, 6:00 AM

Camurus AB: Camurus' Nomination Committee appointed for the Annual General Meeting 2026

Camurus